Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: How to finance healthcare?

Susann Roth, senior social development specialist, Asian Development Bank, looks at financing mechanisms to meet the third Sustainable Development Goal.

Over 20 years ago, during my second year at medical school, I spent my semester break with an Indian nongovernmental organisation providing health services to the urban poor in Kolkata. I soon realised that being a doctor or a nurse accomplishes little if there isn’t enough money to pay for diagnostic tests or medicine.

Later, during some fieldwork in a province in the Philippines when I was working on my master’s degree in public health, I learned that even when funding is available, it does not necessarily result in better health outcomes.

Healthcare, I now know, is essentially a business, and as such needs proper funding mechanisms to deliver quality service.

When we think about financing strategies to meet the third Sustainable Development Goal – to ensure health and well-being for everyone – the first question that comes to mind is, how much will it cost? Probably hundreds of billions of dollars are needed. Health will account for the lion’s share of the US$1.3 trillion that developing Asia is expected to spend on social infrastructure by 2025. And health infrastructure alone is not enough. We will also need to invest in health professionals’ capacity development, as well as in health service delivery.

Economic growth should allow for more government spending on health. But that’s also not enough. Most countries in developing Asia spend far less on health than the Organisation for Economic Co-operation and Development's average and below what the World Health Organisation recommends. Investing in health is still not perceived as cost-efficient to obtain financial returns in the short-to-medium term.

On the positive side, most countries in the region are slowly increasing public health expenditure and are committed to providing universal health coverage. Some countries are scaling up social health insurance and others are exploring how to extend existing financial market instruments such as bonds to the health sector.

As traditional donor grants are harder to come by, it’s time to find new ways to access money. Bonds and blended finance can help, and engaging the private sector will be critical.

Bonds can support large-scale health and social infrastructure investment. Earlier this year, the Asian Development Bank became the first multilateral development bank to launch a health bond, targeting investors keen to contribute to a social cause that can deliver good long-term returns.

Another option is to leverage more blended financing. As more countries graduate from eligibility for concessional financing, blended finance can help make even the most expensive loans more accessible.

Blended finance can entail partnering with donors and negotiating grants beyond country allocations, linked to sector development or policy loans, basically structuring grants around loan policy conditions. This would allow existing non-government health providers to be funded through grants, which is crucial in countries where social contracting with civil society and the private sector is still difficult. Without access to grant financing, governments may be inclined to only finance physical health infrastructure such as hospitals and not the training and reforms that will make universal healthcare possible.

Blended finance can come from foundations or the private sector itself. The key here is to structure the project so that countries get the most bang from their buck from investments; grants target soft sectors such as capacity development, while loans are used more for hard targets such as infrastructure or procurement.

Beyond bonds and blended finance, the third option to increase health funding in developing Asia is to work with the private sector. While there has always been a heated debate about the value addition of the private sector in health, from my point of view it's the best way forward.

Public-private collaboration on health can bring huge benefits to both sides. For instance, pooled procurement of medicine and other health commodities allows the public sector to leverage economies of scale, so it can then negotiate better prices with the private sector and pay less for the same items. This is already happening with vaccines in countries that are graduating from top donor funds.

The public and private sectors can also work together on lease and maintenance arrangements for equipment. This reduces the initial investment burden on the public sector while ensuring longer contracts for private providers. A good example is a pilot programme in remote areas of Myanmar to convert shipping containers into operating rooms equipped with solar panels and telecommunications systems.

The case for more private sector funding in health is clear. The challenge for governments is to create the necessary incentives to make it happen, especially in emerging markets.

One way forward is to identify gaps where the public sector can guarantee payments over the long term to serve low-income populations. A government can, for example, approach a company to set up renal care clinics by committing to pay for a minimum number of dialysis cycles per month. This reduces the risk for the firm entering a new market where most people lack basic insurance and, even if they have it, cannot afford additional chronic out-of-pocket treatment.

Governments can also set up schemes that enable companies to check that their business models are providing accessible, affordable and equitable health care. The private sector stands to benefit – once it overcomes the resistance to invest in low-income settings.

To move forward on health financing in developing Asia, we need solutions as well as money. Funds must be targeted to each country, align with national health plans and be followed by serious government efforts to attract the private sector. Only then can we aspire to attain universal health coverage.

Posted on: 01/08/2017 UTC+08:00


News

Beijing-based healthcare service platform Miaoshou Doctor has completed a ¥1.5 billion (US$232 million) Series F round of financing.
Chinese digital technology company, Xisoft Technology, which focuses on hospital operation management, has raised ¥100 million ($15.65 million) in Series A+ financing.
Hearing health company Olive Union has closed a $7M Series B round led by Beyond Next Ventures, Bonds Investment Groups and Japan Policy Finance Corporation.
Long Hill Capital, a venture capital firm in China, has closed on more than $300 million for its third fund on 15 March.
Eluminex Biosciences, an ophthalmic biotechnology company has completed a $50 million Series A financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital.
TVM Capital Healthcare, a global private equity and growth capital firm focused on emerging markets, has announced two team additions today.
In partnership with VeChain and DNV GL, Renji Hospital, a hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has launched the world's first blockchain-enabled intelligent tumour treatment centre.
Hong Kong-based BuyHive, a new global sourcing start-up that connects buyers with trusted verified overseas suppliers, has launched a PPE programme to help US companies optimise their post-Covid supply chains.



Analysis

L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.


Podcasts

HealthInvestor Asia twitter feed










A Rolex Yacht-Master I Ladies Replica watch is basically a person watch that's crafted inside an identical fashion with a well-known maker¡¯s real piece. Purchasing Replica Watches seems as an excellent idea. Anyway,ON perfectcloneshop.com replica Rolex Yacht-Master Ladies watches are affordable, look almost the identical while using real ones and could easily acquired.